Advanced in Delayed Growth

Dr. David T. Rubin

Family Medicine
1278 60th St, 
Brooklyn, NY 
Advanced in Delayed Growth
1278 60th St, 
Brooklyn, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Rubin is a primary care provider, practicing in Family Medicine in Brooklyn, New York. Dr. Rubin is rated as an Advanced provider by MediFind in the treatment of Delayed Growth. His top areas of expertise are Colitis, Viral Gastroenteritis, Hemorrhagic Proctocolitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 527 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

1278 60th St, Brooklyn, NY 11219
Other Locations
1312 38th St, Brooklyn, NY 11218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other
Study Phase: Phase 4
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen
Enrollment Status: Completed
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 3
Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease
Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
View 9 Less Clinical Trials

527 Total Publications

International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
Journal: Journal of Crohn's & colitis
Published: September 19, 2025
Similar Doctors
Advanced in Delayed Growth
Dr. Eli N. Rosen
Family Medicine
Advanced in Delayed Growth
Dr. Eli N. Rosen
Family Medicine
358 Kingston Ave, 
Brooklyn, NY 
 (3.9 miles away)
718-778-7272
Languages Spoken:
English
See accepted insurances

Eli Rosen is a primary care provider, practicing in Family Medicine in Brooklyn, New York. Dr. Rosen is rated as a Distinguished provider by MediFind in the treatment of Delayed Growth. His top areas of expertise are Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, High Cholesterol, and Cataract Removal.

Advanced in Delayed Growth
Dr. Afshin Shahkoohi
Pediatrics | Family Medicine | Internal Medicine
Advanced in Delayed Growth
Dr. Afshin Shahkoohi
Pediatrics | Family Medicine | Internal Medicine
14 Heyward St, 
Brooklyn, NY 
 (5.3 miles away)
718-260-4600
Languages Spoken:
English
See accepted insurances

Afshin Shahkoohi is a primary care provider, practicing in Pediatrics and Internal Medicine in Brooklyn, New York. Dr. Shahkoohi is rated as a Distinguished provider by MediFind in the treatment of Delayed Growth. His top areas of expertise are Obesity in Children, Food Allergy, Pharyngomaxillary Space Abscess, and Chickenpox.

Experienced in Delayed Growth
Dr. Neil T. Smith
Family Medicine
Experienced in Delayed Growth
Dr. Neil T. Smith
Family Medicine

North Shore-Lij Medical PC

300 Community Dr, 
Manhasset, NY 
 (18.7 miles away)
516-562-3058
Languages Spoken:
English
See accepted insurances

Neil Smith is a primary care provider, practicing in Family Medicine in Manhasset, New York. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Delayed Growth. His top areas of expertise are Phenylketonuria (PKU), Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Obesity in Children.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rubin's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 151 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile